Targeting ATM-deficient CLL through interference with DNA repair pathways

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic lymphocytic leukemia (CLL) is a prevalent leukemia in Western countries, often diagnosed in older adults.
• Genetic aberrations, particularly in the ATM-CHK2-p53 pathway, are linked to aggressive CLL and chemoresistance.
• ATM and TP53 gene alterations are common in CLL, impacting DNA damage response and disease progression.

Purpose of the Study:

• To elucidate the role of ATM signaling in DNA damage response, repair, and leukemogenesis in CLL.
• To explore novel therapeutic strategies for ATM-defective CLL.
• To evaluate the potential of PARP1 and DNA-PKcs inhibitors for treating ATM-mutant CLL.

Main Methods:

• Focus on the ATM signaling pathway's role in DNA damage response and repair.
• Discussion of genetic aberrations (11q deletions, 17p deletions, mutations) affecting ATM and TP53.
• Review of genetically engineered mouse models for CLL research.

Main Results:

• ATM signaling pathway inactivation is a key factor in aggressive CLL and resistance to chemotherapy.
• ATM-mutant CLL clones may be susceptible to targeted therapies.
• Genetically engineered mouse models serve as valuable platforms for therapeutic development.

Conclusions:

• ATM pathway defects significantly contribute to CLL pathogenesis and poor prognosis.
• Targeted inhibition of PARP1 and DNA-PKcs represents a promising therapeutic avenue for ATM-mutant CLL.
• Preclinical models are crucial for advancing novel treatment strategies in CLL.